Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
5,370,110
-
Total 13F shares
-
177,963
-
Share change
-
+14,849
-
Total reported value
-
$1,263,538
-
Price per share
-
$7.10
-
Number of holders
-
9
-
Value change
-
+$105,431
-
Number of buys
-
3
-
Number of sells
-
2
Institutional Holders of Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) as of Q2 2025
As of 30 Jun 2025,
Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
177,963 shares.
The largest 9 holders included
AdvisorShares Investments LLC, Lynx1 Capital Management LP, Prosperity Wealth Management, Inc., CITADEL ADVISORS LLC, Merck & Co., Inc., Cyndeo Wealth Partners, LLC, RHUMBLINE ADVISERS, MORGAN STANLEY, and BANK OF AMERICA CORP /DE/.
This page lists
9
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.